NR3C2 and heart failure: Similarly, the decrease of systolic BP by finerenone was relatively small, but similar to eplerenone in the ARTS-HF (MinerAlocorticoid Receptor antagonist Tolerability Study- Heart Failure) trial: the least squares mean changes of systolic BP were − 2.365 (− 5.287, 0.558) mmHg in the eplerenone group (the average dose of 38.6 mg/day) and − 0.825 (− 3.929, 2.278), − 2.532 (− 5.630, 0.566), − 2.697 (− 5.757, 0.363), and − 2.397 (− 5.348, 0.554) mmHg in the finerenone groups (2.5 to 5, 5 to 10, 7.5 to 15, and 10 to 20 mg daily, respectively) [42].